Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals Inc (NQ: DAWN )

13.46 -0.12 (-0.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 720,973
Open 13.49
Bid (Size) 12.00 (3)
Ask (Size) 14.00 (6)
Prev. Close 13.58
Today's Range 13.33 - 13.75
52wk Range 9.670 - 18.07
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal
FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting... 
Via Talk Markets
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-7.30%
-7.30%
1 Month
+2.12%
+2.12%
3 Month
-15.03%
-15.03%
6 Month
-7.30%
-7.30%
1 Year
+12.64%
+12.64%

More News

Read More
Day One Announces Sale of Priority Review Voucher for $108 Million
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024
Via InvestorPlace
Analyst Ratings for Day One Biopharmaceutical
Via Benzinga
The Latest Analyst Ratings for Day One Biopharmaceutical
Via Benzinga
Where Day One Biopharmaceutical Stands With Analysts
Via Benzinga
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Two New Appointments to Board of Directors
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Dow Up Over 340 Points As Stocks Snap Back
Via Talk Markets
Topics Stocks
Exposures US Equities
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
$15M Bet On Day One Biopharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
$3.6 Bet On Asana? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.